Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H20N6O.2C3H6O2 |
Molecular Weight | 496.5588 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(O)=O.CCC(O)=O.O=C(NC1=CC=CC(=C1)C2=NCCN2)NC3=CC=CC(=C3)C4=NCCN4
InChI
InChIKey=AFGQXWSHYUHHNV-UHFFFAOYSA-N
InChI=1S/C19H20N6O.2C3H6O2/c26-19(24-15-5-1-3-13(11-15)17-20-7-8-21-17)25-16-6-2-4-14(12-16)18-22-9-10-23-18;2*1-2-3(4)5/h1-6,11-12H,7-10H2,(H,20,21)(H,22,23)(H2,24,25,26);2*2H2,1H3,(H,4,5)
Molecular Formula | C19H20N6O |
Molecular Weight | 348.4017 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C3H6O2 |
Molecular Weight | 74.0785 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Imidocarb is a carbanilide derivative with antiprotozoal activity. It is usually administered as the dipropionate salt. Imidocarb is a drug sold under the brand name Imizol and is used to treat canine ehrlichiosis. wo mechanisms of action have been proposed:
As the effect of imidocarb on Trypanosoma brucei is antagonized by excess polyamines, it is has been suggested that imidocarb interferes with their production and/or use. Imidocarb blocks the entry of inositol into erythrocytes containing Babesia, resulting in starvation of the parasite. It is generally accepted in that imidocarb has anticholinesterase activity.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4768 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27301742 |
|||
Target ID: CHEMBL2966 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27301742 |
|||
Target ID: CHEMBL220 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20053484 |
590.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Imizol Approved UseFor the treatment of babesiosis in dogs with clinical signs and/or demonstrated Babesia organisms in the blood. Launch Date1997 |
|||
Curative | IMIDOCARB Approved UseFor treatment of babesiosis in cattle and horses Launch Date2001 |
PubMed
Title | Date | PubMed |
---|---|---|
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992 Sep |
|
Effects of imidocarb dipropionate in cats with chronic haemobartonellosis. | 2002 Summer |
|
In-vivo therapeutic efficacy trial with artemisinin derivative, buparvaquone and imidocarb dipropionate against Babesia equi infection in donkeys. | 2003 Nov |
|
Imidocarb, a potent anti-protozoan drug, up-regulates interleukin-10 production by murine macrophages. | 2003 Sep 19 |
|
[Autochthonous babesiosis in dogs in the Netherlands?]. | 2004 May 1 |
|
First isolation and molecular characterization of Ehrlichia canis in Spain. | 2004 Nov 10 |
|
Detection and molecular characterization of a novel large Babesia species in a dog. | 2004 Oct 5 |
|
[A literature review of equine piroplasmosis after an episode of acute babesiosis in a Dutch Standardbred foal after a stay in Normandy]. | 2005 Dec 1 |
|
Autochthonous canine babesiosis in The Netherlands. | 2005 Jul 15 |
|
Identification of anti-babesial activity for four ethnoveterinary plants in vitro. | 2005 Jun 10 |
|
Clinical and clinicopathological changes in 6 healthy ponies following intramuscular administration of multiple doses of imidocarb dipropionate. | 2005 Mar |
|
Effective imidocarb dipropionate therapy for Babesia shortti in falcons. | 2006 Feb 18 |
|
Failure of imidocarb dipropionate to clear experimentally induced Ehrlichia canis infection in dogs. | 2006 Jul-Aug |
|
Effect of imidocarb and levamisole on the experimental infection of BALB/c mice by Leishmania (Leishmania) amazonensis. | 2006 Jun 30 |
|
Clinicopathological changes and effect of imidocarb therapy in dogs experimentally infected with Babesia canis. | 2006 Mar |
|
Canine babesiosis in France. | 2006 May 31 |
|
Chemotherapy against babesiosis. | 2006 May 31 |
|
Comparison of the efficacy of enrofloxacin, imidocarb, and oxytetracycline for clearance of persistent Anaplasma marginale infections in cattle. | 2006 Winter |
|
Evidence of an acute phase response in dogs naturally infected with Babesia canis. | 2007 Mar 31 |
|
Treatment of Mycoplasma wenyonii infection in cows with imidocarb dipropionate injection-acupuncture. | 2008 Dec |
|
The clinical course of babesiosis in 76 dogs infected with protozoan parasites Babesia canis canis. | 2009 |
|
Putative clinical piroplasmosis in a Burchell's zebra (Equus quagga burchelli). | 2009 Dec |
|
Canine babesiosis: from molecular taxonomy to control. | 2009 Mar 26 |
|
Babesia and its hosts: adaptation to long-lasting interactions as a way to achieve efficient transmission. | 2009 Mar-Apr |
|
Detection of a large unnamed Babesia piroplasm originally identified in dogs in North Carolina in a dog with no history of travel to that state. | 2009 Oct 1 |
|
Canine babesiosis in northern Portugal and molecular characterization of vector-borne co-infections. | 2010 Apr 8 |
|
First case of babesiosis caused by Babesia canis canis in a dog from Norway. | 2010 Aug 4 |
|
Haemotropic mycoplasmas: what's their real significance in cats? | 2010 May |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/vet/imizol.html
Use intramuscularly or subcutaneously at a rate of 6.6 mg/kg (3 mg/lb) body weight. Repeat the dose in two (2) weeks, for a total of two (2) treatments.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2242963
The concentration of Imidocarb causing 50% inhibition of [3H]hypoxanthine incorporation (ID50 value) by Babesia bovis (Lismore and Samford isolates) cultured in vitro for Imidocarb was determined to be 3 ng/ml (8.6 nM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:13:55 GMT 2025
by
admin
on
Mon Mar 31 18:13:55 GMT 2025
|
Record UNII |
ZSM1M03SHC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 522.1156
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
||
|
CFR |
21 CFR 522.1155
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID4046604
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
Imidocarb dipropionate
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
1740238
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
ZSM1M03SHC
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
9983292
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
259-791-8
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
C76007
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
55750-06-6
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
300000023751
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
ZSM1M03SHC
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
C031719
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
DBSALT001684
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
|
||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |